OREANDA-NEWS. As the head of Rospotrebnadzor Anna Popova said on October 27, production of the Epivakkoron coronavirus vaccine, developed by the State Scientific Center for Virology and Biotechnology Vector, has begun.

She said that the production of the vaccine has begun at Vektor and promised that the necessary volumes of the vaccine will already be produced by the end of the year.

Elena Gavrilova, deputy director general for scientific work of the center, said that they are talking about a viral vector vaccine based on influenza, measles, as well as synthetic vaccines. She said that they also tried to work with an inactivated vaccine at the center. She added that six out of 10 technology platforms in the world were used in the development of the vaccine.

It should be recalled that the Russian center "Vector" on July 24 received permission from the Ministry of Health of the Russian Federation to conduct clinical trials of the vaccine on volunteers. The first volunteer was vaccinated on 27 July. The final group of 20 volunteers who participated in the clinical trials were discharged from the hospital on September 8. Anna Popova also said that clinical trials of the vaccine ended on September 30.

On October 14, it was announced that the vaccine from the Vector Center had received an official marketing authorization. The center will begin post-registration clinical trials in various regions of Russia with the participation of 40 thousand volunteers.